TABLE 2

Diagnostic potential of mutations at known resistance-conferring locia

DrugGeneMutationFrequencyPPVSensitivitySpecificity
RifampinAny7010.991
rpoBD435Yb,c210.031
H445D/L/Yb,c1910.271
S450L/Wb,c4910.691
IsoniazidAny720.990.970.96
katGS315Tc7110.971
inhAc-15tc260.960.340.96
t-8a/cc2610.361
OfloxacinAny4310.911
gyrAA90Vc1410.281
S91Pc410.081
D94A/G/H/N/Yc2510.501
gyrBD461N210.041
N499T110.021
KanamycinAny400.900.730.91
rrsa1400gc3110.611
c1483tc110.021
eisg-10a2000.96
c-14t60.670.080.96
AmikacinAny3210.861
rrsa1400gc3110791
c1483tc110.031
CapreomycinAny350.970.830.98
rrsa1400gc3110.721
c1483tc110.021
tlyALOF30.670.050.98
StreptomycinAny7010.931
rpsLK43R4110.551
K88R310.041
rrsa513c1910.251
a516t610.081
gidBLOF210.031
PyrazinamideAny310.161
pncALOF310.161
EthambutolAny630.980.900.96
embBM306I/Vc380.970.530.96
G406D110.011
Q497R2410.341
EthionamideAny650.3510.42
ethALOF470.360.740.59
inhAc-15tc260.500.570.82
t-8a/cc260.230.260.73
  • a Isolates were included only if they had both phenotypic and genotypic resistance predictions. For each mutation, we show frequency of the mutation in the data set, positive predictive value (PPV), sensitivity, and specificity for predicting phenotypic resistance. Mutations are listed as either specific changes or as any loss-of-function (LOF) mutation, including nonsense mutations and frameshifts.

  • b Mutation detectable by GeneXpert MTB/RIF.

  • c Mutation detectable by MTBDRplus version 2.0 or MTBDRsl version 1.0.